Search hospitals > Pennsylvania > Pittsburgh
Allegheny General Hospital
Claim this profilePittsburgh, Pennsylvania 15212
Global Leader in Hypertension
Global Leader in Skin Cancer
Conducts research for Breast Cancer
Conducts research for Pulmonary Hypertension
Conducts research for Pulmonary Arterial Hypertension
473 reported clinical trials
61 medical researchers
Summary
Allegheny General Hospital is a medical facility located in Pittsburgh, Pennsylvania. This center is recognized for care of Hypertension, Skin Cancer, Breast Cancer, Pulmonary Hypertension, Pulmonary Arterial Hypertension and other specialties. Allegheny General Hospital is involved with conducting 473 clinical trials across 699 conditions. There are 61 research doctors associated with this hospital, such as Thomas Krivak, Gene G. Finley, Sarah Crafton, and Dulabh Monga, MD.Area of expertise
1Hypertension
Global Leader2Skin Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Thomas KrivakWest Penn Hospital5 years of reported clinical research
Expert in Ovarian Cancer
Studies Skin Cancer
14 reported clinical trials
36 drugs studied
Gene G. FinleyAllegheny General Hospital10 years of reported clinical research
Studies Colon Cancer
Studies Lung Cancer
12 reported clinical trials
41 drugs studied
Sarah CraftonWest Penn Hospital5 years of reported clinical research
Studies Ovarian Cancer
Studies Endometrial Cancer
13 reported clinical trials
22 drugs studied
Dulabh Monga, MDAllegheny General Hospital5 years of reported clinical research
Studies Pancreatic Cancer
Studies Hepatocellular Carcinoma
10 reported clinical trials
29 drugs studied
Clinical Trials running at Allegheny General Hospital
Skin Cancer
Lung Cancer
Breast Cancer
Bladder Cancer
Bladder Carcinoma
Liver Cancer
Non-Small Cell Lung Cancer
Cardiovascular Disease
Squamous Cell Carcinoma
Prostate Cancer
Pump Chemotherapy
for Colorectal Cancer
This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the liver (liver metastases) and cannot be removed by surgery (unresectable). HAI uses a catheter to carry a tumor-killing chemotherapy drug called floxuridine directly into the liver. HAI is already approved by the Food and Drug Administration (FDA) for use in metastatic colorectal cancer to the liver, but it is only available at a small number of hospitals, and most of the time it is not used until standard chemotherapy stops working. Standard chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding HAI to standard chemotherapy may be effective in shrinking or stabilizing unresectable colorectal liver metastases.
Recruiting2 awards Phase 37 criteria
Disitamab Vedotin + Pembrolizumab vs Chemotherapy
for Bladder Cancer
This study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than platinum-containing chemotherapy to treat patients with UC. This study will also test what side effects happen when participants take these drugs together. A side effect is anything a drug does to the body besides treating the disease. Participants in this study will have cancer that has spread through the body (metastatic) or spread near where it started (locally advanced). In this study, there are 2 different groups. Participants will be assigned to a group randomly. Participants in the disitamab vedotin arm will get the study drug disitamab vedotin once every two weeks and pembrolizumab once every 6 weeks. Participants in the standard of care arm will get gemcitabine once a week for 2 weeks with either cisplatin or carboplatin once every 3 weeks.
Recruiting2 awards Phase 3
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Allegheny General Hospital?
Allegheny General Hospital is a medical facility located in Pittsburgh, Pennsylvania. This center is recognized for care of Hypertension, Skin Cancer, Breast Cancer, Pulmonary Hypertension, Pulmonary Arterial Hypertension and other specialties. Allegheny General Hospital is involved with conducting 473 clinical trials across 699 conditions. There are 61 research doctors associated with this hospital, such as Thomas Krivak, Gene G. Finley, Sarah Crafton, and Dulabh Monga, MD.
Where is Allegheny General Hospital located?
**Directions to Allegheny General Hospital, Pittsburgh, Pennsylvania:**
- From the North: Take I-79 South to I-279 South, then I-279 North to East Street Exit (Exit 2B). Turn right onto North Avenue, then right onto James Street, and left into the parking garage.
- From the West/Pittsburgh International Airport: Take I-79 South to I-376, then I-279 North across the Fort Pitt Bridge. Take the East Ohio Street Exit (Exit 1D), turn left onto East Ohio Street, then right onto James Street, and left into the parking garage.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance inquiries at Allegheny General Hospital, contact AHN Patient Financial Services at 1-833-684-0239. For details on the Financial Assistance program, call 1-855-493-2500 or email financialadvocates@ahn.org. The Financial Assistance Application can be downloaded and submitted with proof of income for eligibility determination.
What insurance does Allegheny General Hospital accept?
Allegheny General Hospital, part of the Allegheny Health Network (AHN), accepts a wide range of insurance plans including Aetna, Anthem, Cigna, Humana, UnitedHealthcare, and many others. AHN has a close relationship with Highmark Blue Cross Blue Shield, serving Western and Northeastern Pennsylvania, with most Highmark plans accepted at AHN facilities within the state. However, UPMC plans may not be fully accepted at all AHN hospitals, with UPMC for Life Medicare Advantage members having full in-network access to AHN primary care physicians, specialists, and hospitals.
What awards or recognition has Allegheny General Hospital received?
Allegheny General Hospital, located in Pittsburgh, Pennsylvania, is distinguished by its Magnet recognition from the American Nurses Credentialing Center for nursing excellence. It is also recognized as a Mitral Valve Repair Reference Center by the American Heart Association and the Mitral Foundation, showcasing its expertise in cardiovascular care.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.